1 |
Scelfo C, ElSheikh RH, Shamim MM, Abbasian J, Ghaffarieh A, Elhusseiny AM. Ocular Surface Disease in Glaucoma Patients. Curr Eye Res 2023;48:219-30. [PMID: 35179417 DOI: 10.1080/02713683.2022.2041041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Vasdev N, Chaudhari N, Polaka S, Rajpoot K, Gondaliya P, Sayyed AA, Sengupta P, Tekade RK. Current progress in preservative-free topical ophthalmic formulations. Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.103996] [Reference Citation Analysis]
|
3 |
Oddone F. Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open angle glaucoma and ocular hypertension management: a focus on efficacy, safety and tolerability. Expert Opin Drug Saf 2022. [PMID: 36250245 DOI: 10.1080/14740338.2022.2135701] [Reference Citation Analysis]
|
4 |
Jansook P, Loftsson T. Aqueous Prostaglandin Eye Drop Formulations. Pharmaceutics 2022;14. [PMID: 36297577 DOI: 10.3390/pharmaceutics14102142] [Reference Citation Analysis]
|
5 |
Lee D, Ha SJ. Long-term Effects of Latanoprost with Different Excipient Compositions on Intraocular Pressure, Hyperemia and Discomfort. J Korean Ophthalmol Soc 2022;63:754-761. [DOI: 10.3341/jkos.2022.63.9.754] [Reference Citation Analysis]
|
6 |
Kim JM, Sung KR, Kim HK, Park SW, Lee EJ, Jeoung JW, Park HL, Ahn J, Yoo C, Kim CY. Long-Term Effectiveness and Safety of Tafluprost, Travoprost, and Latanoprost in Korean Patients with Primary Open-Angle Glaucoma or Normal-Tension Glaucoma: A Multicenter Retrospective Cohort Study (LOTUS Study). J Clin Med 2021;10:2717. [PMID: 34205421 DOI: 10.3390/jcm10122717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|